Viewing Study NCT02864992

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:36 PM
Ignite Modification Date: 2026-02-25 @ 8:25 PM
Study NCT ID: NCT02864992
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-23
First Post: 2016-07-29
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Sponsor: EMD Serono Research & Development Institute, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET … View
None Lung Adenocarcinoma Stage IIIB/IV View
Keywords:

Keywords

Keyword Brief Keyword Text View
None lung View
None neoplasm View
None cancer View
None tumor View
None adenocarcinoma View
None MET exon 14 View
None METex14 View
None pulmonary View
None stage III View
None stage IV View
None c-Met View
None cMET View
None NSCLC View
None advanced non-small cell lung cancer View
None MET amplification View
None non-small cell lung cancer View